Metabasis Therapeutics, Inc. (Nasdaq: MBRX) announced that its four year research collaboration with Merck & Co., Inc. (NYSE: MRK), focused ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE